<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433859</url>
  </required_header>
  <id_info>
    <org_study_id>2013RC09</org_study_id>
    <secondary_id>2014-002068-34</secondary_id>
    <nct_id>NCT03433859</nct_id>
  </id_info>
  <brief_title>Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)</brief_title>
  <acronym>SALUTOX</acronym>
  <official_title>Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Aluminium Chloride to OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate onabotulinumtoxinA superiority to aluminium chloride
      for the treatment of residual limb hyperhidrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomization patients will receive either OnabotulinumtoxinA once or topical aluminium
      chloride for 6 months. All patients will be evaluated during 3 study visits (week 4, week 12,
      week 24) and 1 phone call (week 18).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperhidrosis Disease Severity Score (HDSS) evolution</measure>
    <time_frame>24 weeks</time_frame>
    <description>HDSS score : min 1 - max. 4
Efficacy : HDSS evolution from 2 (initial measure) to 1 (final measure), from 3 (initial measure) to 1 or 2 (final measure), from 4 (initial measure) to 1 or 2 (final measure)
Failure : from 2 (initial measure) to 2 (final measure), from 3 or 4 (initial measure) to 2 (final measure) ; or increase of HDSS between initial and final measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mismatch of prothesis associated with sweat measured by a visual analogue scale</measure>
    <time_frame>3 years</time_frame>
    <description>Visual analogue scale (VAS) using 100mm scale. VAS range from 0 to 100mm. Efficacy is considered if &gt; 50% increase between initial and final measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Problems with walking due to sweat measured by a visual analogue scale</measure>
    <time_frame>3 years</time_frame>
    <description>Visual analogue scale (VAS) using 100mm scale. VAS range from 0 to 100mm. Efficacy is considered if &gt; 50% increase between initial and final measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sweat quantity measured by a visual analogue scale</measure>
    <time_frame>3 years</time_frame>
    <description>Visual analogue scale (VAS) using 100mm scale. VAS range from 0 to 100mm. Efficacy is considered if &gt; 50% increase between initial and final measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by a visual analogue scale</measure>
    <time_frame>3 years</time_frame>
    <description>Visual analogue scale (VAS) using 100mm scale. VAS range from 0 to 100mm. Efficacy is considered if &gt; 50% increase between initial and final measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of time spent wearing the prothesis</measure>
    <time_frame>3 years</time_frame>
    <description>Amount of time spent wearing the prosthesis (hours per day): efficacy if increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothesis removed to dry the residual limb</measure>
    <time_frame>3 years</time_frame>
    <description>Number of times the prosthesis had to be removed to dry the residual limb and sleeve per day: efficacy if no need to remove it or only once a day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(DLQI)</measure>
    <time_frame>3 years</time_frame>
    <description>DLQI quality of life questionnaire : efficacy if increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (physical domain of SF36)</measure>
    <time_frame>3 years</time_frame>
    <description>SF36 &quot;limitations due to physical state&quot; specific domain : efficacy if increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (subjective improvement felt)</measure>
    <time_frame>3 years</time_frame>
    <description>Subjective Improvement Felt (SIF) (based on a percentage scale) :efficacy if&gt;50% increase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hyperhidrosis</condition>
  <condition>Residual Limbs</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA in intradermal Injections on residual lower limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Aluminium Chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Aluminium Chloride (cosmetic product) on the lower limb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose</description>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Aluminium Chloride (cosmetic product)</intervention_name>
    <description>Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb</description>
    <arm_group_label>Topical Aluminium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lower limb amputees suffering from residual limb hyperhidrosis with important
             cutaneous, functional, social and professional consequences, whatever the amputation
             cause

          -  HDSS ≥ 2 (Hyperhidrosis Disease Severity Score)

          -  Men and women

          -  18 to 75 years old

          -  Written informed consent

          -  No exclusion criteria

          -  Social assurance

        Exclusion Criteria:

          -  Botulinum toxin injection necessity for another disease

          -  Evolutive Central neurologic disease or myasthenia.

          -  Egg or albumine allergy

          -  Botulinum toxin or other excipients hypersensibility

          -  Legally protected Adults and people unable to give an informed consent. (article
             L-1121-8 from Public Health Code), people without freedom and people hospitalized
             without consent (article L-1121-6 from Public Health Code)

          -  Pregnant women or giving breast women (article L-1121-5 from Public Health)

          -  Patient refusing participating

          -  Previous hyperhidrosis treatment with aluminium chloride in the last 4 weeks

          -  Previous hyperhidrosis treatment with botulinum toxin in the last 2 years

          -  Other ongoing hyperhidrosis treatment

          -  Large residual limb eczematiform lesions: corticoids treatment (for example: Locapred®
             1 application per day during 1 week then decrease).

          -  Aminoglycoside ongoing treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène BISSERIEX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Santé des Armées, Hôpital Clermont-Tonnerre (Brest, France)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène BISSERIEX, MD</last_name>
    <phone>+33(0)298437303</phone>
    <email>helene.bisseriex@intradef.gouv.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Les Capucins</name>
      <address>
        <city>Angers</city>
        <zip>49103</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick BRUNEL, MD</last_name>
      <phone>+33(0)241351701</phone>
      <email>patrick.brunel@les-capucins-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Clermont-Tonnerre</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène BISSERIEX, MD</last_name>
      <phone>+33(0)298437303</phone>
      <email>helene.bisseriex@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CMPR La Tour de Gassies</name>
      <address>
        <city>Bruges</city>
        <zip>33523</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémi KLOTZ, M.D.</last_name>
      <phone>+33(0)5 56 16 32 92</phone>
      <email>rklotz.gassies@ugecamaq.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo BORRINI, MD</last_name>
      <phone>+33(0)141466284</phone>
      <email>leo.borrini@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Laveran</name>
      <address>
        <city>Marseille</city>
        <zip>13384</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent THEFENNE, MD</last_name>
      <phone>+33(0)491617132</phone>
      <email>laurent.thefenne@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pôle Saint Helier</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie LEBLONG, M.D.</last_name>
      <phone>+33(0)2 99 29 50 88</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre La Tourmaline</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44818</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique EVENO, MD</last_name>
      <phone>+33(0)240385746</phone>
      <email>deveno@ugecam-brpl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Réadaptation Clémenceau</name>
      <address>
        <city>Strasbourg</city>
        <zip>67082</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu BERTHEL, MD</last_name>
      <phone>+33(0)388211694</phone>
      <email>mathieu.berthel@ugecam-alsace.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Robert Merle d'Aubigné, IRMA</name>
      <address>
        <city>Valenton</city>
        <zip>94460</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souhila CHAIBEDDRA TANI, M.D.</last_name>
      <phone>+33(0)1 45 10 80 80</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Aluminum chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

